Publications by authors named "Peter Button"

Claim this Profile
T
The smallest worthwhile effects of strengthening exercise on pain intensity for people with knee osteoarthritis: A benefit-harm trade-off study.
Travis Haber, Kim Bennell, Harrison Hansford, James McAuley, Peter Button

Osteoarthritis Cartilage· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.
Ian R Woodcock, George Tachas, Nuket Desem, Peter J Houweling, Michael Kean, Peter Button

PLoS One· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Living With Hereditary Angioedema in Australia: Findings From a National Observational Study Using Short Message Service to Monitor the Burden of Disease.
Constance H Katelaris, Kathryn Boicos, Peter H Button, Philip I McCloud, Pamela K Burton

J Allergy Clin Immunol Pract· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA).
Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, Peter Button, Bianca Devitt

Int J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial.
Alex Castellarnau, Graham P Heery, Aynaz Seta, Carolyn A Luscombe, George R Kinghorn, Peter Button

Sci Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
Jia-Min B Pang, Belinda Castles, David J Byrne, Peter Button, Shona Hendry

Am J Surg Pathol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset.
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird

J Rheumatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies.
Boulos Haraoui, Gustavo Casado, László Czirják, Andrew Taylor, Lingli Dong, Peter Button

Rheumatol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Yi-Long Wu, Victor Lee, Chong-Kin Liam, Shun Lu, Keunchil Park, Peter Button

Lung Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
Dave Nicholls, Rina Barrett, Peter Button, Matt Truman, Paul Bird

Intern Med J· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Button

Int J Rheum Dis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
Keunchil Park, Chong-Jen Yu, Sang-We Kim, Meng-Chih Lin, Virote Sriuranpong, Peter Button

JAMA Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications.
Matthew T Kitson, Stuart K Roberts, John C Colman, Eldho Paul, Peter Button

Scand J Gastroenterol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Michael Michael, Shane C White, Ehtesham Abdi, Louise Nott, Phillip Clingan, Peter Button

Asia Pac J Clin Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection.
Matthew T Kitson, Jacob George, Gregory J Dore, Reynold Leung, Peter Button

J Gastroenterol Hepatol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection".
Matthew T Kitson, Peter Button, Stuart K Roberts,

J Hepatol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.
Matthew T Kitson, Gregory J Dore, Jacob George, Peter Button, Geoffrey W McCaughan

J Hepatol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.
Michael Bilous, Adrienne L Morey, Jane E Armes, Richard Bell, Peter H Button

Breast Cancer Res Treat· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Yung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, Hyun Cheol Chung, Young-Kyu Park, Peter Button

Lancet· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Andrew M Wardley, Xavier Pivot, Flavia Morales-Vasquez, Luis M Zetina, Maria de Fátima Dias Gaui, Peter Button

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
Teerha Piratvisuth, George Lau, You-Chen Chao, Rui Jin, Anuchit Chutaputti, Peter Button

Hepatol Int· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
Michael W Fried, Teerha Piratvisuth, George K K Lau, Patrick Marcellin, Wan-Cheng Chow, Peter Button

Hepatology· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
Patrick Marcellin, George K K Lau, Ferruccio Bonino, Patrizia Farci, Stephanos Hadziyannis, Peter Button

N Engl J Med· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis